NASH AMPK Exercise Dosing (AMPED) Trial
ConditionNAFLD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-69
SponsorMilton S. Hershey Medical Center
About this trial
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD.
While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.
Eligibility criteria
Qualifiers
Age 18-69 years
Sedentary [<90 min/wk of exercise identified by the Get Active Questionnaire (GAQ)
BMI >25kg/m2
NASH defined by NASH Clinical Research Network (CRN) histology scoring system (NAS) >4 and MRI-PDFF >5% and;
Disqualifiers
Active cardiac symptoms
Body mass index (BMI) >45kg/m2
Cancer that is active
Inability to walk >2 blocks
Trial design
Treatments tested in this trial
- Exercise
Treatment groups
45 Participants
are divided into 3 treatment groupsSponsors and collaborators
Milton S. Hershey Medical Center
Lead sponsor
Penn State Health Milton S Hershey Medical Center
Sponsor institution
Source ClinicalTrials.gov